datopotamab deruxtecan + pembrolizumab + carboplatin

This is a **three-drug combination regimen** consisting of: - **datopotamab deruxtecan** (Dato-DXd), an antibody-drug conjugate targeting TROP2, - **pembrolizumab**, an anti-PD-1 immune checkpoint inhibitor monoclonal antibody, - **carboplatin**, a platinum-based cytotoxic chemotherapy agent. The combination is being investigated for first-line treatment of locally advanced or metastatic **non-small-cell lung cancer (NSCLC)**, particularly for patients without actionable genomic alterations, and especially those with lower PD-L1 expression. Dato-DXd delivers a cytotoxic payload to TROP2-expressing cancer cells, pembrolizumab reactivates anti-tumor immunity by blocking PD-1 on T cells, and carboplatin induces DNA damage to rapidly dividing cells[1][9]. Currently, development is focused in advanced/metastatic NSCLC, with different cohorts including treatment-naïve and previously treated patients, as well as those with varying PD-L1 expression[1][9]. Combination regimens with Dato-DXd and pembrolizumab with or without platinum chemotherapy are in phase 3 studies and dose-finding trials[1][9].

Brand names

Keytruda (pembrolizumab; only applies to this ingredient)

Other names

datopotamab deruxtecan + pembrolizumab + carboplatin